GLP1R and type 2 diabetes mellitus: The underlying deficit of GLP-1 in type 2 diabetes could also be involved in the impairment of sleep breathing, and the potential benefit of incretin-based therapies needs to be evaluated (ClinicalTrials.gov: NCT02889510).